文献速递青光眼神经眼科

双重食欲素受体拮抗剂减轻大鼠下丘脑刺激后眼压、颅内压及跨筛板压力差的升高

Dual Orexin Receptor Antagonist Attenuates Increases in IOP, ICP, and Translaminar Pressure Difference After Stimulation of the Hypothalamus in Rats.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2022-01-01

研究在大鼠下丘脑DMH/PeF区注射GABA-A受体拮抗剂BMI以兴奋神经元,观察预先全身给予双重食欲素受体拮抗剂DORA-12对眼压、颅内压及跨筛板压力差的影响。结果显示30 mg/Kg DORA-12使眼压峰值降低5.2 ± 3.6 mm Hg(P = 0.007),并降低TLPD的AUC;作者认为DORA可能减轻中枢神经系统激活引起的眼压与颅内压异步变化及TLPD波动。

要点

  • 30 mg/Kg DORA-12预处理使下丘脑刺激后眼压峰值降低5.2 ± 3.6 mm Hg(P = 0.007)。
  • 30 mg/Kg DORA组在峰值反应期(8-40分钟)的眼压AUC显著低于对照组(P = 0.04)。
  • DORA预处理显著降低DMH/PeF刺激后TLPD的AUC(10 mg/kg P = 0.045,30 mg/kg P = 0.015)。

核心结论

  • DORA具有减轻眼压与颅内压异步变化、减小中枢神经系统激活所致TLPD波动的潜力。

研究设计与样本

  • Sprague Dawley大鼠全身预处理DORA-12 30 mg/Kg(n = 8)、10 mg/Kg(n = 8)或溶剂对照(n = 8),记录DMH/PeF微注射BMI前后眼压、颅内压、心率和平均动脉压。

主要发现

  • 30 mg/Kg DORA-12使眼压峰值降低5.2 ± 3.6 mm Hg(P = 0.007)。
  • 峰值反应期(8-40分钟)30 mg/Kg DORA组的眼压AUC显著低于同期对照组(P = 0.04)。
  • 0至30 mg/Kg范围内,眼压峰值AUC与DORA剂量呈线性关系(R2 = 0.18,P = 0.04)。
  • 峰值反应期(4-16分钟)颅内压与DORA剂量呈线性关系(R2 = 0.24,P = 0.014)。
  • DORA预处理显著降低DMH/PeF刺激后TLPD的AUC(10 mg/kg P = 0.045,30 mg/kg P = 0.015)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intraocular pressure (IOP) remains the only modifiable risk factor for glaucoma progression. Our previous discovery that stimulation of nuclei within the hypothalamus can modulate IOP, intracranial pressure (ICP), and translaminar pressure difference (TLPD) fluctuations led us to investigate this pathway further. Our purpose was to determine the role of orexin neurons, primarily located in the dorsomedial hypothalamus (DMH) and perifornical (PeF) regions of the hypothalamus, in modulating these pressures. METHODS: Sprague Dawley rats were pretreated systemically with a dual orexin receptor antagonist (DORA-12) at 30 mg/Kg (n = 8), 10 mg/Kg (n = 8), or vehicle control (n = 8). The IOP, ICP, heart rate (HR), and mean arterial pressure (MAP) were recorded prior to and following excitation of the DMH/PeF using microinjection of the gamma-aminobutyric acid (GABA)A receptor antagonist bicuculline methiodide (BMI). RESULTS: Administration of the DORA at 30 mg/Kg significantly attenuated peak IOP by 5.2 ± 3.6 mm Hg (P = 0.007). During the peak response period (8-40 minutes), the area under the curve (AUC) for the 30 mg/Kg DORA cohort was significantly lower than the control cohort during the same period (P = 0.04). IOP responses for peak AUC versus DORA dose, from 0 to 30 mg/Kg, were linear (R2 = 0.18, P = 0.04). The ICP responses during the peak response period (4-16 minutes) versus DORA dose were also linear (R2 = 0.24, P = 0.014). Pretreatment with DORA significantly decreased AUC for the TLPD following stimulation of the DMH/PeF (10 mg/kg, P = 0.045 and 30 mg/kg, P = 0.015). CONCLUSIONS: DORAs have the potential to attenuate asynchronous changes in IOP and in ICP and to lessen the extent of TLPDs that may result from central nervous system (CNS) activation.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. DeCarlo AA, Hammes N, Johnson PL, et al. Dual Orexin Receptor Antagonist Attenuates Increases in IOP, ICP, and Translaminar Pressure Difference After Stimulation of the Hypothalamus in Rats. Invest Ophthalmol Vis Sci. 2022. PMID: 35234838. doi:10.1167/iovs.63.3.1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。